Skip to content

Claire Moore

5 papers in the library · 13 citations · publishing 2022-2024

Papers

Sort Most recent Most cited

Harnessing Pharmacogenomics in Clinical Research on Psychedelic‐Assisted Therapy

Clinical Pharmacology & Therapeutics September 30, 2024 Andreas Halman, Rachel Conyers, Claire Moore et al. 13 citations

Psychedelics have recently re‐emerged as potential treatments for various psychiatric conditions that impose major public health costs and for which current treatment options have limited efficacy. At the same time, personalized medicine is increasingly being implemented in psychiatry to provide individualized drug dosing recommendations based on genetics. This review brings together these...

Ketamine-Assisted Group Psychotherapy for Frontline Healthcare Workers with COVID-19-Related Burnout and PTSD: A Case Series of Effectiveness/Safety for 10 Participants.

Journal of Psychoactive Drugs 2024 Reid Robison, Madeline Brendle, Claire Moore et al.

This study reports on 10 frontline healthcare workers, employed during the COVID-19 pandemic and experiencing symptoms of burnout and PTSD, treated with group ketamine-assisted psychotherapy (KAP) in a private outpatient clinic setting. Participants attended 6 sessions once weekly. These included 1 preparation session, 3 ketamine sessions (2 sublingual, 1 intramuscular), 2 integration sessions....

Breathwork Interventions for Adults with Clinically Diagnosed Anxiety Disorders: A Scoping Review.

Brain Sciences February 2, 2023 Blerida Banushi, Madeline Brendle, Anya Ragnhildstveit et al.

Anxiety disorders are the most common group of mental disorders, but they are often underrecognized and undertreated in primary care. Dysfunctional breathing is a hallmark of anxiety disorders; however, mainstays of treatments do not tackle breathing in patients suffering anxiety. This scoping review aims to identify the nature and extent of the available research literature on the efficacy of...

A case series of group-based ketamine-assisted psychotherapy for patients in residential treatment for eating disorders with comorbid depression and anxiety disorders.

Journal of Eating Disorders May 6, 2022 Reid Robison, Adele Lafrance, Madeline Brendle et al.

Depression and anxiety outcome measures, safety/tolerability, patient satisfaction, and ease of implementation of group-based ketamine-assisted psychotherapy (G-KAP) delivered to patients in intensive residential eating disorder (ED) treatment were assessed. This study reports on five participants with a diagnosis of an ED and comorbid mood and anxiety disorders who received weekly...

Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions.

Brain Sciences March 12, 2022 Anya Ragnhildstveit, Matthew Slayton, Laura Kate Jackson et al.

Eating disorders (EDs) are serious, life-threatening psychiatric conditions associated with physical and psychosocial impairment, as well as high morbidity and mortality. Given the chronic refractory nature of EDs and the paucity of evidence-based treatments, there is a pressing need to identify novel approaches for this population. The noncompetitive N-methyl-D-aspartate receptor (NMDAr)...